Real Patient Cases
Review how these real patients responded to adding Optune Gio to their treatment
Select a patient case below to learn more about their treatment journey1
76, male
Biospsy only
58, female
MGMT-unmethylated
41, male
IDH1-mutated
61, female
2 year Optune Gio user
Consider adding Optune Gio for older patients like this one
Patient 1
76 years old
Biopsy only
MGMT-methylated
- Married, 4 grandchildren
- Retired painter
- Supported by his wife and daughter
Meta-analysis limitations1
- All studies included in the analysis were retrospective and lacked randomization between treatment groups
- Additional prognostic factors beyond those routinely captured for patients with GBM and reported here may exist
- Patterns related to how long patients sustain treatment with Optune Gio could not be evaluated and remain unknown
Results of the meta-analysis showed that Optune Gio + SP* consistently improved OS vs SP* alone1-3
- 37% reduction in the risk of death with Optune Gio + SP* vs SP* alone (HR: 0.63 [95% CI, 0.53-0.75])1
Continued treatment with Optune Gio
Optune Gio + adjuvant chemotherapy
- Optune Gio + adjuvant chemotherapy initiated 6 weeks after chemoradiation
- Temozolomide completed after 7 monthly cycles at 150 mg/m2 (dosing due to fatigue and thrombocytopenia)
Lorem ipsum